Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 20/20 | 0.38 |
| ▸ | CCNC | P24863 | 19/20 | 0.38 |
| ▸ | CDK8 | P49336 | 19/20 | 0.38 |
| ▸ | CDK19 | Q9BWU1 | 12/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18572432 | 0.90 | CCNC (0.38) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL1450415 | 0.77 | ALDH1A1 (0.54) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL18572729 | 0.75 | HASPIN (0.43) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL18572714 | 0.73 | CCNC (0.43) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL20747127 | 0.73 | CCNC (0.46) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL30953660 | 0.71 | HASPIN (0.38) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL20747125 | 0.69 | KDM4E (0.49) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL18572718 | 0.68 | KDM4E (0.54) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL18572113 | 0.68 | HASPIN (0.45) | HASPINCCNCCDK8CDK19 | |
| SCHEMBL18572986 | 0.68 | CCNC (0.36) | HASPINCCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341376-B1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO (ES) | 2020-12-23 | — | — | EP | disclosed |
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2019-02-19 | — | — | US | disclosed |
| WO-2017033019-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (CNIO) (ES) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | CDK8, CDK18, CDK2 | HASPIN 6/4885CCNC 34/4885CDK8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.